Fundraising FoxVistaGen Therapeutics
NASDAQ: VTGNSouth San Francisco, US · Nevada corporation · 1 known investors
Find your way into VistaGen Therapeutics
Sign up to see every warm intro you have to VistaGen Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the VistaGen Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
VistaGen Therapeutics develops intranasal pherine compounds targeting neuropsychiatric and women's health conditions through a mechanism that activates nasal sensory neurons to modulate brain circuits without systemic absorption. The company's pipeline includes fasedienol in Phase 3 trials for acute social anxiety disorder, along with earlier-stage candidates for depression, menopausal hot flashes, mental fatigue, and cancer cachexia.
Founders & leadership
HR
H. Ralph SnodgrassFounder
JD
Jerrold D. DotsonExecutive
SK
Shawn K. SinghExecutiveShawn K. Singh is President and CEO of VistaGen Therapeutics, a public biotechnology company developing intranasal pherine compounds for neuropsychiatric and women's health conditions. He brings 30 years of experience in biotechnology and biopharmaceutical industries, with expertise in public company management, corporate finance, strategic partnerships, and regulatory affairs, and holds a J.D. from the University of Maryland Francis King Carey School of Law.
AF
A. Franklin RiceVice President of Corporate Development
Board
UJ
Underdown J. BrianBoard director
GA
Gregory A. BonfiglioBoard director
BJ
Brian J. UnderdownBoard director
JS
Jon S. SaxeBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$13.2M disclosed across 7 of 8 rounds · 2012–2023
▶$2.8MofferedFeb 2023 · 129 investors · PharmaceuticalsRule 506(b)
▶$2.8MofferedFeb 2023 · 129 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jerrold D. DotsonExecutive Officer
- Joanne CurleyDirector
- Shawn K. SinghExecutive Officer, Director
- Jon S. SaxeDirector
- Jerry B. GinDirector
- Ann M. CunninghamDirector
- Reid G. AdlerExecutive Officer
- Margaret FitzPatrickDirector
- Mary L. RotunnoDirector
- Offering amount
- $2.8M
- First sale
- Feb 2023
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$2.8MraisedJan 2020 · 3 investors · PharmaceuticalsRule 506(b)
▶$2.8MraisedJan 2020 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Mark McPartlandExecutive Officer
- Ann K. CunninghamDirector
- Mark A. SmithExecutive Officer
- Jerry B. GinDirector
- Brian J. UnderdownDirector
- Jon S. SaxeDirector
- H. Ralph SnodgrassExecutive Officer, Director
- Jerrold D. DotsonExecutive Officer
- Shawn K. SinghExecutive Officer, Director
- Offering amount
- $2.8M
- Amount sold
- $2.8M
- Minimum investment
- $250K
- First sale
- Jan 2020
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$650KraisedDec 2019 · 7 investors · BiotechnologyRule 506(b)
▶$650KraisedDec 2019 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark A. SmithExecutive Officer
- Jerry B. GinDirector
- Mark McPartlandExecutive Officer
- H. Ralph SnodgrassExecutive Officer, Director
- Brian J. UnderdownDirector
- Jerrold D. DotsonExecutive Officer
- Jon S. SaxeDirector
- Shawn K. SinghExecutive Officer, Director
- Ann K. CunninghamDirector
- Offering amount
- $650K
- Amount sold
- $650K
- First sale
- Oct 2019
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$4.8MraisedSep 2018 · 33 investors · BiotechnologyRule 506(b)
▶$4.8MraisedSep 2018 · 33 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- H. Ralph SnodgrassExecutive Officer, Director
- Mark A. SmithExecutive Officer
- Jerry B. GinDirector
- Mark McPartlandExecutive Officer
- Brian J. UnderdownDirector
- Jerrold D. DotsonExecutive Officer
- Jon S. SaxeDirector
- Shawn K. SinghExecutive Officer, Director
- Offering amount
- $5.8M
- Amount sold
- $4.8M
- First sale
- Jun 2018
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$1MraisedAug 2017 · 14 investors · BiotechnologyRule 506(b)
▶$1MraisedAug 2017 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jon S. SaxeDirector
- H. Ralph SnodgrassExecutive Officer, Director
- Jerry B. GinDirector
- Shawn K. SinghExecutive Officer, Director
- Mark A. SmithExecutive Officer
- Jerrold D. DotsonExecutive Officer
- Brian J. UnderdownDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Mar 2017
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$1.9MraisedAug 2015 · 15 investors · BiotechnologyRule 506(b)
▶$1.9MraisedAug 2015 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jon S. SaxeDirector
- Underdown J. BrianDirector
- H. Ralph SnodgrassExecutive Officer, Director
- Jerrold D. DotsonExecutive Officer
- Shawn K. SinghExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $1.9M
- First sale
- May 2015
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$1.6MraisedJun 2014 · 21 investors · BiotechnologyRule 506(b)
▶$1.6MraisedJun 2014 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brian J. UnderdownDirector
- Jerrold D. DotsonExecutive Officer
- H. Ralph SnodgrassExecutive Officer, Director
- Shawn K. SinghExecutive Officer, Director
- Jon S. SaxeDirector
- Offering amount
- $3M
- Amount sold
- $1.6M
- Minimum investment
- $5K
- First sale
- Mar 2014
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$500KraisedMar 2012 · 6 investors · BiotechnologyRule 506(b)
▶$500KraisedMar 2012 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shawn K. SinghExecutive Officer, Director
- Jon S. SaxeDirector
- Jerrold D. DotsonExecutive Officer
- H. Ralph SnodgrassExecutive Officer, Director
- Gregory A. BonfiglioDirector
- Brian J. UnderdownDirector
- A. Franklin RiceExecutive Officer
- Offering amount
- $3M
- Amount sold
- $500K
- Minimum investment
- $25K
- Sales commissions
- $21K
- Placement agents
- Noble Financial Capital Markets
- First sale
- Feb 2012
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does VistaGen Therapeutics do?
- VistaGen Therapeutics develops intranasal pherine compounds targeting neuropsychiatric and women's health conditions through a mechanism that activates nasal sensory neurons to modulate brain circuits without systemic absorption. The company's pipeline includes fasedienol in Phase 3 trials for acute social anxiety disorder, along with earlier-stage candidates for depression, menopausal hot flashes, mental fatigue, and cancer cachexia.
- Who founded VistaGen Therapeutics?
- VistaGen Therapeutics was founded by H. Ralph Snodgrass.
- Who are VistaGen Therapeutics's investors?
- VistaGen Therapeutics's investors include New Enterprise Associates (NEA).
- How much funding has VistaGen Therapeutics raised?
- VistaGen Therapeutics has disclosed $13.2M raised across 7 of its 8 known rounds.
- Where is VistaGen Therapeutics headquartered?
- VistaGen Therapeutics is headquartered in South San Francisco, US.